NASDAQ$TOI
Oncology Institute Inc/The · Q3 2022 earnings
Q3 2022 earnings · · Investor relations
Briefing
The Oncology Institute's value-based care model and growth strategy were highlighted.
The Oncology Institute's investor presentation highlighted their position as a leading value-based oncology care platform, emphasizing their disruptive model, growth opportunities, and financial overview, including a revenue guidance of $245 to $250 million for 2022.
- The Oncology Institute (TOI) is disrupting oncology care with a unique value-based model.
- TOI's technology platform standardizes and aligns care delivery at scale.
- The company has demonstrated new market exportability and has predictable, repeatable, and scalable growth.
- Tremendous near-term and long-term growth opportunities exist for TOI.
Headline financials
Revenue & EPS history
Oncology Institute · Revenue · Quarterly
$65M
Revenue by segment
Oncology Institute · $63.5M total across 2 segments · Q3 2022
- Patient Services$44.6M—70.3%
- Dispensary$18.8M—29.7%
Forward guidance
The Oncology Institute projects continued growth and profitability, driven by value-based care contracts, expansion into new markets, and strategic acquisitions.
Tailwinds
- New markets launch with FFS + Gainshare
- Acquisition CAGR (Top-line): 18%
- Acquisition EBITDA accretive: Year 1
- DeNovo CAGR (Top-line): 53%
- Conversion to Capitated Contracts by year 4: enabling Gross Margins >25%
Headwinds
- Adjusted EBITDA and Net Income Protability projected in 2024
- Acquisitions
- De Novo Growth
- Operating Losses
- Working Capital (predominantly funding A/R)
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q3 2022
+2.6%
Avg return
Earnings day
+2.7%
Avg return
5 days after
+8.0%
Avg return
30 days after
62%
13 / 21 earnings
Positive
+28.9%
Q3 2025
Best reaction
-23.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | +6.8% | +5.8% | +27.9% | |
| Q4 2025 | +8.4% | +37.4% | +17.6% | |
| Q3 2025 | +28.9% | +6.2% | +22.7% | |
| Q1 2025 | +28.3% | +17.3% | +4.2% | |
| Q4 2024 | +24.5% | +14.5% | +189.2% | |
| Q3 2024 | -23.4% | -43.8% | -5.1% | |
| Q2 2024 | -20.4% | -11.1% | -26.9% | |
| Q1 2024 | +3.6% | -26.5% | -46.6% | |
| Q4 2023 | +8.9% | -7.7% | -32.0% | |
| Q3 2023 | +5.7% | +46.6% | -27.6% | |
| Q2 2023 | -10.1% | -13.3% | +28.3% | |
| Q1 2023 | +4.2% | -6.3% | +29.2% | |
| Q4 2022 | +1.9% | -5.8% | -30.6% | |
| Q3 2022 | -4.3% | -35.5% | -66.4% | |
| Q2 2022 | +0.6% | -1.2% | -9.6% | |
| Q1 2022 | -14.7% | -11.8% | -6.5% | |
| Q2 2021 | +10.3% | +31.4% | +48.1% | |
| Q4 2020 | +10.3% | +31.4% | +48.1% | |
| Q4 2021 | -14.6% | +18.5% | +26.5% | |
| Q3 2021 | +0.0% | +10.0% | -23.6% | |
| Q1 2021 | -0.2% | +1.0% | +0.7% |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro